Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Pembrolizumab Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

March 2nd 2020

Pembrolizumab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared with brentuximab vedotin in adult patients with relapsed/refractory classic Hodgkin lymphoma, meeting one of the dual primary endpoints of the phase III KEYNOTE-204 trial.

Next Chapter Begins With CAR T-Cell Therapy in Myeloma

March 1st 2020

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Unmet Needs Remain in GVHD, But Novel Approaches on Horizon

March 1st 2020

Corey S. Cutler, MD, MPH, discusses how physicians can optimize treatment management in patients with both acute and chronic graft-versus-host-disease.

Dr. Radich on the Evolving Role of MRD in Hematologic Malignancies

March 1st 2020

Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.

Deep Data Dive Needed for Upfront Treatment Selection in iNHL

February 29th 2020

At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.

Experts Share Common Misconceptions in Their Fields

February 29th 2020

OncLive interviewed experts at the State of the Science Summits™ in February 2020 on common misconceptions in their respective fields.

Dr. Cortes on Tyrosine Kinase Inhibitors in CML

February 29th 2020

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.

Dr. Khaled on Recognition and Treatment of TA-TMA

February 29th 2020

Samer K. Khaled, MD, discusses current recognition and treatment strategies for transplant-associated thrombotic microangiopathy.

Dr. Ramakrishnan on Updates in DLBCL

February 29th 2020

Praveen Ramakrishnan, MD, assistant professor, Department of Internal Medicine, UT Southwestern Medical Center, discusses updates in diffuse large B-cell lymphoma (DLBCL) that were presented at the 2019 ASH Annual Meeting.

Dr. Heyman on the Use of Maintenance Rituximab in Follicular Lymphoma

February 29th 2020

Benjamin Heyman, MD, assistant clinical professor of medicine, University of California, San Diego, discusses the use of maintenance rituximab (Rituxan) in patients with follicular lymphoma.

Expanded Choices Emerge for Myelofibrosis Following Ruxolitinib Therapy

February 29th 2020

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

Park Touts Further Developments, Unmet Needs With CAR T-Cell Therapy in ALL

February 28th 2020

Jae H. Park, MD, discusses the challenges in using CAR T-cell therapy in adult patients with acute lymphoblastic leukemia, and also highlights the potential role for off-the-shelf CAR T cells.

Novel Approaches Gain Ground in Diffuse Large B-Cell Lymphoma

February 28th 2020

Despite advances made in the treatment of patients with diffuse large B-cell lymphoma, investigators are on a quest to move more novel agents through the pipeline, says Craig Moskowitz, MD, in a presentation during the 24th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma.

Gemtuzumab Ozogamicin Misses Early EFS Endpoint, as Phase III Study Continues in NPM1+ AML

February 26th 2020

Gemtuzumab ozogamicin in combination with intensive induction therapy was associated with a higher early death rate compared with induction therapy alone in patients with NPM1-mutated acute myeloid leukemia.

Dr. Daver on Azacitidine and Nivolumab in Acute Myeloid Leukemia

February 26th 2020

Naval G. Daver, MD, discusses the rationale of azacitidine and nivolumab in acute myeloid leukemia.

Dr. Blum on the Current Treatment Landscape of Acute Myeloid Leukemia

February 26th 2020

William G. Blum, MD, discusses the current treatment landscape of acute myeloid leukemia.

Optimal Treatment Selection Needed in Advanced Follicular Lymphoma

February 26th 2020

Benjamin Heyman, MD, discusses frontline and maintenance therapy options, novel targeted approaches, and the expanding role of minimal residual disease in patients with follicular lymphoma.

Long-Term Data Spark Investigation of Brentuximab Combos in Hodgkin Lymphoma Subgroups

February 25th 2020

Ayad Hamdan, MD, discusses the impact of the 4-year follow-up data from the ECHELON-1 trial in advanced-stage Hodgkin lymphoma.

Dr. Vusirikala on Hyper-CVAD Plus Ponatinib in Philadelphia Chromosome-Positive ALL

February 25th 2020

Madhuri Vusirikala, MD, discusses the benefit of hyper-CVAD and ponatinib in patients with Philadelphia chromosome–positive ALL.

Standard Myeloma Therapies Transform to Triplet, Quadruplet Regimens

February 25th 2020

Caitlin Costello, MD, discusses pivotal research in the relapsed/refractory multiple myeloma setting.